Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Richard F. Pops
CEORichard F. Pops
Employees
2,050
Employees2,050
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
2,050
Employees2,050

ALKS Key Statistics

Market cap
8.22B
Market cap8.22B
Price-Earnings ratio
127.25
Price-Earnings ratio127.25
Dividend yield
Dividend yield
Average volume
1.91M
Average volume1.91M
High today
$50.00
High today$50.00
Low today
$48.52
Low today$48.52
Open price
$49.80
Open price$49.80
Volume
1.60M
Volume1.60M
52 Week high
$55.67
52 Week high$55.67
52 Week low
$25.17
52 Week low$25.17

Stock Snapshot

Alkermes(ALKS) stock is priced at $48.99, giving the company a market capitalization of 8.22B. It carries a P/E multiple of 127.25.

As of 2026-08-03, Alkermes(ALKS) stock has fluctuated between $48.52 and $50.00. The current price stands at $48.99, placing the stock +1.0% above today's low and -2.0% off the high.

Alkermes(ALKS) shares are trading with a volume of 1.6M, against a daily average of 1.91M.

In the last year, Alkermes(ALKS) shares hit a 52-week high of $55.67 and a 52-week low of $25.17.

In the last year, Alkermes(ALKS) shares hit a 52-week high of $55.67 and a 52-week low of $25.17.

ALKS News

TipRanks 1d
Alkermes Earnings Call Highlights Orexin-Fueled Growth

Alkermes plc ((ALKS)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with Ti...

Simply Wall St 2d
Why Alkermes Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing

In late July 2026, Alkermes plc reported second-quarter 2026 results showing revenue of US$496.01 million versus US$390.66 million a year earlier, while net inc...

Why Alkermes Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing
TipRanks 5d
Alkermes price target raised to $58 from $48 at Baird

Baird raised the firm’s price target on Alkermes (ALKS) to $58 from $48 and keeps an Outperform rating on the shares. The firm updated its model following Q2 re...

Analyst ratings

72%

of 18 ratings
Buy
72.2%
Hold
22.2%
Sell
5.6%

More ALKS News

Simply Wall St 5d
Alkermes Could Be 11% Above Fair Value As Earnings Land】【。

Alkermes (ALKS) reported second quarter 2026 results on July 28, with revenue of US$496.01 million and net income of US$0.501 million, following a period of str...

Alkermes Could Be 11% Above Fair Value As Earnings Land】【。
Nasdaq 6d
Alkermes Reports Break-Even Earnings for Q2

Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per...

Alkermes Reports Break-Even Earnings for Q2

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.